ProCE Banner Activity

Current Use of PARP Inhibitors in Prostate Cancer: Rationale and Key Data

Slideset Download
Review expert slides tailored for urologists on key data and ongoing trials of single-agent and combination therapy with PARP inhibitors for patients with metastatic prostate cancer.

Released: October 17, 2022

Expiration: October 16, 2023

Share

Faculty

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Faculty Disclosure

Primary Author

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California